Peter B Gilbert1, Erin E Gabriel2, Xiaopeng Miao3, Xiaoming Li4, Shu-Chih Su5, Janie Parrino5, Ivan S F Chan5. 1. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington. 2. National Institute of Allergy and Infectious Diseases, Biostatistics Research Branch, Bethesda, Maryland. 3. Department of Biometrics, Biogen Idec, Cambridge, Massachusetts. 4. Biostatistics, Gilead Sciences, Seattle, Washington. 5. Merck, Whitehouse Station, New Jersey.
Abstract
BACKGROUND: The phase III Zostavax Efficacy and Safety Trial of 1 dose of licensed zoster vaccine (ZV; Zostavax; Merck) in 50-59-year-olds showed approximately 70% vaccine efficacy (VE) to reduce the incidence of herpes zoster (HZ). An objective of the trial was to assess immune response biomarkers measuring antibodies to varicella zoster virus (VZV) by glycoprotein-based enzyme-linked immunosorbent assay as correlates of protection (CoPs) against HZ. METHODS: The principal stratification vaccine efficacy curve framework for statistically evaluating immune response biomarkers as CoPs was applied. The VE curve describes how VE against the clinical end point (HZ) varies across participant subgroups defined by biomarker readout measuring vaccine-induced immune response. The VE curve was estimated using several subgroup definitions. RESULTS: The fold rise in VZV antibody titers from the time before immunization to 6 weeks after immunization was an excellent CoP, with VE increasing sharply with fold rise: VE was estimated at 0% for the subgroup with no rise and at 90% for the subgroup with 5.26-fold rise. In contrast, VZV antibody titers measured 6 weeks after immunization did not predict VE, with similar estimated VEs across titer subgroups. CONCLUSIONS: The analysis illustrates the value of the VE curve framework for assessing immune response biomarkers as CoPs in vaccine efficacy trials. CLINICAL TRIALS REGISTRATION: NCT00534248.
RCT Entities:
BACKGROUND: The phase III Zostavax Efficacy and Safety Trial of 1 dose of licensed zoster vaccine (ZV; Zostavax; Merck) in 50-59-year-olds showed approximately 70% vaccine efficacy (VE) to reduce the incidence of herpes zoster (HZ). An objective of the trial was to assess immune response biomarkers measuring antibodies to varicella zoster virus (VZV) by glycoprotein-based enzyme-linked immunosorbent assay as correlates of protection (CoPs) against HZ. METHODS: The principal stratification vaccine efficacy curve framework for statistically evaluating immune response biomarkers as CoPs was applied. The VE curve describes how VE against the clinical end point (HZ) varies across participant subgroups defined by biomarker readout measuring vaccine-induced immune response. The VE curve was estimated using several subgroup definitions. RESULTS: The fold rise in VZV antibody titers from the time before immunization to 6 weeks after immunization was an excellent CoP, with VE increasing sharply with fold rise: VE was estimated at 0% for the subgroup with no rise and at 90% for the subgroup with 5.26-fold rise. In contrast, VZV antibody titers measured 6 weeks after immunization did not predict VE, with similar estimated VEs across titer subgroups. CONCLUSIONS: The analysis illustrates the value of the VE curve framework for assessing immune response biomarkers as CoPs in vaccine efficacy trials. CLINICAL TRIALS REGISTRATION: NCT00534248.
Authors: Myron J Levin; Kenneth E Schmader; John W Gnann; Shelly A McNeil; Timo Vesikari; Robert F Betts; Susan Keay; Jon E Stek; Nickoya D Bundick; Shu-Chih Su; Yanli Zhao; Xiaoming Li; Ivan S F Chan; Paula W Annunziato; Janie Parrino Journal: J Infect Dis Date: 2013-08-01 Impact factor: 5.226
Authors: Kenneth E Schmader; Richard Sloane; Carl Pieper; Paul M Coplan; Alexander Nikas; Patricia Saddier; Ivan S F Chan; Peter Choo; Myron J Levin; Gary Johnson; Heather M Williams; Michael N Oxman Journal: Clin J Pain Date: 2007 Jul-Aug Impact factor: 3.442
Authors: Kathleen Hempenstall; Turo J Nurmikko; Robert W Johnson; Roger P A'Hern; Andrew S C Rice Journal: PLoS Med Date: 2005-07-26 Impact factor: 11.069
Authors: Peter B Gilbert; Erin E Gabriel; Michael G Hudgens; Xiaopeng Miao; Xiaoming Li; Shu-Chih Su; Janie Parrino; Ivan S F Chan Journal: J Infect Dis Date: 2015-05-17 Impact factor: 5.226
Authors: Peter B Gilbert; Ying Huang; Michal Juraska; Zoe Moodie; Youyi Fong; Alexander Luedtke; Yingying Zhuang; Jason Shao; Lindsay N Carpp; Nicholas Jackson; Laurent Chambonneau; Alain Bouckenooghe; Betzana Zambrano; Carina Frago; Sophie Pallardy; Fernando Noriega Journal: Am J Trop Med Hyg Date: 2019-07 Impact factor: 2.345
Authors: Rachel A Bender Ignacio; Meena S Ramchandani; Kerry J Laing; Christine M Johnston; David M Koelle Journal: Viral Immunol Date: 2016-11-21 Impact factor: 2.257
Authors: Zoe Moodie; Michal Juraska; Ying Huang; Yingying Zhuang; Youyi Fong; Lindsay N Carpp; Steven G Self; Laurent Chambonneau; Robert Small; Nicholas Jackson; Fernando Noriega; Peter B Gilbert Journal: J Infect Dis Date: 2018-02-14 Impact factor: 5.226
Authors: Constance A Benson; Janet W Andersen; Bernard J C Macatangay; Robbie B Mailliard; Charles R Rinaldo; Sarah Read; Dawn R Bozzolo; Lynette Purdue; Cheryl Jennings; Michael C Keefer; Marshall Glesby; Pablo Tebas; Amy Falk Russell; Jason Martin; Paula Annunziato; Zoran Popmihajlov; Jeffrey L Lennox Journal: Clin Infect Dis Date: 2018-11-13 Impact factor: 9.079